Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma
Status:
Terminated
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
In summary, the overall prognosis of glioblastoma (GBM) patients remains poor. Although
clinical gains have been achieved in the past, these have been modest, with a majority of
patients succumbing to local disease progression within 2 years. New strategies for treatment
need to be identified which enhance local control above the current treatment regimen in
order to achieve further clinical gains in this disease. Favorable early experience with
magnetic resonance spectroscopy imaging (MRSI) demonstrates that metabolic imaging can
identify active tumor beyond standard MRI as well as high risk regions at risk for local
failure. There is also clinical evidence that limited field dose escalation with either
simultaneous integrated boost (SIB) or stereotactic radiosurgery (SRS) is feasible and safe.
Coupling these findings provide the rationale for this proposed Phase II trial designed to
define efficacy and toxicity of the novel treatment approach of whole brain volumetric 3D
MRSI guided dose-escalated radiation therapy (RT) in newly diagnosed GBM patients.